Inflammation plays a significant role in the multifactorial pathogenesis of DME1-4
Hyperglycemia-induced inflammation affects many tissues in the body, including the eye.5,6
Inflammatory mediators cause the breakdown of the blood retinal barrier.1,2 Excess fluids and lipids accumulate in the macula leading to edema which can result in vision loss.1,2
Hyperglycemia1,2
Understanding of the multiple factors involved in the pathophysiology of DME continues to advance.
Images owned by AbbVie.
Signs of inflammation or chronic DME such as large cysts, hyperreflective foci and subretinal fluid/serous retinal detachment can be identified using OCT.3
Abbreviations and references
DME, diabetic macular edema; ICAM-1, intercellular adhesion molecule 1; IL-1β, interleukin 1 beta; IL-6, interleukin 6; MCP-1, monocyte chemoattractant protein 1; TNF-α, tumour necrosis factor alfa; VEGF, vascular endothelial growth factor.
1. Bahrami B et al. Diabetologia 2016; 59: 1594-608.
2. Urias EA et al. Vision Res 2017; 139: 221-7.
3. Munk MR et al. Int J Mol Sci 2022; 23: 7585.
4. Noma H et al. Int J Mol Sci 2021; 22: 3427.
5. Dong N et al. Mol Vision 2013; 19: 1734-46.
6. Garcia-Layana A et al. Ophthalmologica 2018; 240(2): 61-72.
Job Number ALL-OZU-220048. Date of Preparation March 2023
OZURDEX® (dexamethasone intravitreal implant) is indicated for the treatment of adult patients with:
- Visual impairment due to diabetic macular edema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy
- Macular edema following either branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO)
- Inflammation of the posterior segment of the eye presenting as non-infectious uveitis
Adverse events should be reported. Reporting forms and information can be found at XXXX
Adverse events should also be reported to AbbVie on GVPV@abbvie.com
Our therapy areas
Additional info
Report Adverse Event (AE reporting requirements to be localized)
This website is for Healthcare Professionals only
Job Number ALL-OZU-220048. Date of Preparation March 2023. This website has been developed and funded by AbbVie Ltd.
© 2019 AbbVie Ltd. All rights reserved. Registered number: 08004972 England.